达比加群：血栓栓塞性疾病治疗与预防的一种新治疗选择？ - Suppr

Suppr

超能文献

[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

作者信息

Gassanov N, Caglayan E, Erdmann E, Er F

机构信息

Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln.

出版信息

Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26.

DOI:10.1055/s-0030-1247864

PMID:20104442

Abstract

摘要

相似文献

[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26.

Dabigatran: new drug. Continue to use heparin, a better-known option.

Prescrire Int. 2009 Jun;18(101):97-9.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19.

Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.

Curr Opin Investig Drugs. 2007 Sep;8(9):758-68.

Dabigatran etexilate: a new oral thrombin inhibitor.

Circulation. 2011 Apr 5;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31.

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:17S-24S. doi: 10.1177/1076029609344588. Epub 2009 Aug 19.

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

作者信息

Gassanov N, Caglayan E, Erdmann E, Er F

机构信息

Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln.

出版信息

Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26.

DOI:10.1055/s-0030-1247864

PMID:20104442

Abstract

摘要

相似文献

[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26.

Dabigatran: new drug. Continue to use heparin, a better-known option.

Prescrire Int. 2009 Jun;18(101):97-9.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19.

Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.

Curr Opin Investig Drugs. 2007 Sep;8(9):758-68.

Dabigatran etexilate: a new oral thrombin inhibitor.

Circulation. 2011 Apr 5;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31.

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:17S-24S. doi: 10.1177/1076029609344588. Epub 2009 Aug 19.

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29.